VLGC Virologic (MM)

ViroLogic to Host Third Quarter 2004 Financial Results Conference Call on Monday, November 15, 2004 at 8:30 a.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (NASDAQ:VLGC) announced that it will hold a conference call on Monday, November 15, 2004 at 8:30 a.m. ET to discuss third quarter 2004 financial results. The call will be hosted by Mr. William D. Young, Chairman & CEO of ViroLogic, Inc. To participate in the teleconference please call 1-866-800-8652 fifteen minutes before the conference begins. International callers please dial 617.614.2705. The participant passcode is 22871658. A replay of the call will also be available at (888) 286-8010 or 617-801-6888 for international callers, until November 26. The replay passcode is 39389010. The call will also be webcast live at http://www.virologic.com/. Please see web site for details. About ViroLogic ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company's products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its website at http://www.virologic.com/ . Forward Looking Statements Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from anticipated results or expectations and include, but are not limited to, the timing of customer clinical trials, risks related to our pending merger with ACLARA, including the risk that the closing conditions of the merger may not be satisfied and the merger may not be completed, and costs related to the proposed merger may adversely impact ViroLogic's financial performance and/or condition, the risks that the Company's products may not perform, whether ViroLogic successfully introduces new products, risks related to the implementation of the Company's distribution agreement with Quest Diagnostics, whether others introduce competitive products, the risk that the Company's products may not continue to be accepted or that increased demand may not develop as anticipated, the risk that gross margins may not increase as expected, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic's products or services, whether the Company will encounter problems or delays in automating its processes, whether intellectual property underlying the Company's technology is adequate, whether licenses to third party technology will be available, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of these and other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and the amended Joint Proxy/Prospectus related to the proposed merger with ACLARA, as well as other subsequent filings with the Securities and Exchange Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Investor Relations of ViroLogic, Inc., +1-650-635-1100 Web site: http://www.virologic.com/

Copyright